Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor — Stella

Home/Intradialytic Hypotension/

View on ClinicalTrials.gov

Recruiting

Back to Intradialytic Hypotension trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

United States

Vanderbilt Fresenius, Nashville, Tennessee

Key details

Phase

Large-scale testing

Sponsor

Vanderbilt University Medical Center

Collaborators

Pharvaris Netherlands B.V., Renal Research Institute

Enrollment target

~26 participants

Started

December 2023

Primary completion

July 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years – 80 Years

Last updated April 2026